Tumour markers.
Tumour markers are now used in the diagnosis, anatomical localization, staging, monitoring and definition of prognosis of a wide range of malignancies. The last decade has seen an expansion of our definition of these markers to include oncogenes and oncogene products, and provided us with new possibilities of developing more specific tests to help in the management of cancer.
Pandha
H S
HS
Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Waxman
J
J
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D006063:Chorionic Gonadotropin / Q000097:blood; D018997:Chorionic Gonadotropin, beta Subunit, Human; D002869:Chromosome Aberrations; D025063:Chromosome Disorders; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000737:chemistry / Q000175:diagnosis*; D015513:Oncogene Proteins / Q000097:blood; D009857:Oncogenes; D010446:Peptide Fragments / Q000097:blood; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D000509:alpha-Fetoproteins / Q000032:analysis
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D015513:Oncogene Proteins; D010446:Peptide Fragments; D000509:alpha-Fetoproteins; D017430:Prostate-Specific Antigen